Merle Myerson1, Eduard Poltavskiy, Ehrin J Armstrong, Shari Kim, Victoria Sharp, Heejung Bang. 1. *Division of Cardiology, Cardiovascular Disease Prevention Program, Mount Sinai Roosevelt and St. Luke's Hospital, New York, NY; †Institute of Advanced Medicine, Spencer Cox Center for Health, Mount Sinai Health System, New York, NY; ‡Department of Statistics, University of California at Davis, Davis, CA; §Division of Cardiology, Department of Medicine, University of Colorado, Denver, CO; and ‖Division of Biostatistics, Department of Public Health Sciences, University of California at Davis, Davis, CA.
Abstract
OBJECTIVE: Patients with HIV may have an increased risk of cardiovascular disease (CVD). The objective of this study was to determine the prevalence, treatment, and control of low-density lipoprotein cholesterol (LDL-C) dyslipidemia and hypertension in a population of HIV-infected patients at an HIV/AIDS clinic in New York City. METHODS: Review of electronic medical records of 4278 HIV-infected patients aged 20 years or older in a racially and ethnically diverse urban HIV/AIDS clinic based in a large tertiary hospital and designated New York State AIDS Center that provides comprehensive care. LDL-C dyslipidemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III goals and hypertension according to Joint National Committee VII criteria. RESULTS: The prevalence of LDL-C dyslipidemia was 35%. Ninety percent of patients with LDL-C dyslipidemia were treated and 75% of those treated were at goal. Patients in high-risk groups (56%), including known coronary heart disease (57%) or coronary heart disease equivalents (62%), were less likely to be at LDL-C goal. The prevalence of hypertension was 43%. Seventy-five percent of patients with hypertension were treated but only 57% overall were at goal. CONCLUSIONS: Although most patients with HIV and LDL-C dyslipidemia or hypertension are treated, a significant percentage did not have adequate control of these risk factors. As patients with HIV are at higher risk for CVD and living to an age where CVD is more common, it will be important to identify ways to better manage and control CVD risk factors in this patient population. A comprehensive care model such as our setting may serve as an option.
OBJECTIVE:Patients with HIV may have an increased risk of cardiovascular disease (CVD). The objective of this study was to determine the prevalence, treatment, and control of low-density lipoprotein cholesterol (LDL-C) dyslipidemia and hypertension in a population of HIV-infectedpatients at an HIV/AIDS clinic in New York City. METHODS: Review of electronic medical records of 4278 HIV-infectedpatients aged 20 years or older in a racially and ethnically diverse urban HIV/AIDS clinic based in a large tertiary hospital and designated New York State AIDS Center that provides comprehensive care. LDL-C dyslipidemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III goals and hypertension according to Joint National Committee VII criteria. RESULTS: The prevalence of LDL-C dyslipidemia was 35%. Ninety percent of patients with LDL-C dyslipidemia were treated and 75% of those treated were at goal. Patients in high-risk groups (56%), including known coronary heart disease (57%) or coronary heart disease equivalents (62%), were less likely to be at LDL-C goal. The prevalence of hypertension was 43%. Seventy-five percent of patients with hypertension were treated but only 57% overall were at goal. CONCLUSIONS: Although most patients with HIV and LDL-C dyslipidemia or hypertension are treated, a significant percentage did not have adequate control of these risk factors. As patients with HIV are at higher risk for CVD and living to an age where CVD is more common, it will be important to identify ways to better manage and control CVD risk factors in this patient population. A comprehensive care model such as our setting may serve as an option.
Authors: Yunan Xu; Xinguang Chen; Akemi Wijayabahu; Zhi Zhou; Bin Yu; Emma C Spencer; Robert L Cook Journal: Curr HIV Res Date: 2020 Impact factor: 1.581
Authors: Shia T Kent; Greer A Burkholder; Gabriel S Tajeu; E Turner Overton; Paul Muntner Journal: Curr Hypertens Rep Date: 2015-11 Impact factor: 5.369
Authors: Jeffrey J Weiss; Ioannis Konstantinidis; Anna Boueilh; Daniel S Fierer; Donald Gardenier; Mark G Barber; Tony Kang; Anna Kress; Katherine Ericson; Marlene C Lira; Marina P Yostos; Hillary R Bogner; Juan P Wisnivesky; Christina M Wyatt Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Nwora Lance Okeke; Allison R Webel; Hayden B Bosworth; Angela Aifah; Gerald S Bloomfield; Emily W Choi; Sarah Gonzales; Sarah Hale; Corrilynn O Hileman; Virginie Lopez-Kidwell; Charles Muiruri; Megan Oakes; Julie Schexnayder; Valerie Smith; Rajesh Vedanthan; Chris T Longenecker Journal: Am Heart J Date: 2019-07-18 Impact factor: 4.749
Authors: Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel Journal: AIDS Res Hum Retroviruses Date: 2018-11-27 Impact factor: 2.205
Authors: David E Wallace; Michael A Horberg; Debra A Benator; Alan E Greenberg; Amanda D Castel; Anne K Monroe; Lindsey Powers Happ Journal: AIDS Care Date: 2020-08-18
Authors: Mikaela Smit; Rosan A van Zoest; Brooke E Nichols; Ilonca Vaartjes; Colette Smit; Marc van der Valk; Ard van Sighem; Ferdinand W Wit; Timothy B Hallett; Peter Reiss Journal: Clin Infect Dis Date: 2018-02-10 Impact factor: 9.079